Overview

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

Status:
Recruiting
Trial end date:
2024-11-22
Target enrollment:
Participant gender:
Summary
A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Merck Sharp & Dohme Corp.